Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Canadian Journal of Infectious Diseases

Volumn 13, Issue 1, 2002, Pages 13-16

  Conly, J M ^a   Johnston, B L ^a  

^a Centre for Antimicrobial Resistance   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; MOXIFLOXACIN; PENICILLIN G; RIBOSOME PROTEIN; RNA 23S; SPIRAMYCIN; TELITHROMYCIN;

AGE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL MENINGITIS; CANADA; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OTITIS MEDIA; SINUSITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0036239531     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/501543     Document Type: Article

References (58)

1. Pneumococcal vaccine
2. Invasive pneumococcal infections: A comparison between adults and children
3. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
4. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia
5. The prevalence of drugresistant Streptococcus pneumoniae in Atlanta
6. The spread of multiple-resistant Streptococcus pneumoniae at a day care centre in Ohio
7. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994
8. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
9. Oral empiric treatment of community acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
10. Pneumococcal disease in Sweden: Experiences and current situation
11. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer
12. Pan American Health Organization Epidemiologic Surveillance Network for Streptococcus pneumoniae
13. Invasive pneumococcal disease in Canada, 1996: Results from the Sentinel Health Unit Surveillance system
14. Assessing the potential impact of vaccination programs on invasive pneumococcal disease: Data from population-based surveillance
15. Management of infections caused by antibiotic resistant Streptococcus pneumoniae
16. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
17. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae: An overview
18. The continued emergence of drug-resistant pneumococcal infections in the United States
19. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America
20. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U.S. study
21. Increasing prevalence of multi-drug resistant in the United States: A report from multi-state population-based surveillance
22. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98
23. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea
24. Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan
25. Emergence of multiple antibiotic-resistant Streptococcus pneumoniae in Hong Kong
26. Antimicrobial resistance in Streptococcus pneumoniae: An epidemiological survey in France, 1970-1990
27. Spread of multidrug-resistant Streptococcus pneumoniae in South Korea
28. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
29. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999
30. Limiting the spread of resistant pneumococci: Biological and epidemiologic evidence for the effectiveness of alternative interventions
31. Determination of macrolide resistance mechanisms in Streptococcus pneumoniae isolated in the PROTEKT 2000 study
32. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America
33. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumonia isolates over a 5-year period of decreased macrolide susceptibility rates
34. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci
35. Invasive pneumococcal infections: A comparison between adults and children
36. Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective
37. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987
38. Macrolide resistance among invasive Streptococcus pneumoniae isolates
39. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(a) and erm(B) and susceptibilities to ketolides
40. Antimicrobial resistance of 1, 113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
41. Infections caused by erythromycin resistant Streptococcus pneumoniae: Incidence, risk factors, and response to therapy in a prospective study
42. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children
43. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae
44. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee
45. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens
46. Three-year multicenter surveillance of systemic pneumococcal infections in children
47. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against S pneumoniae based on serum and intrapulmonary pharmacokinetics
48. Pneumococcal macrolide resistance: Not a myth
49. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption
50. Sparfloxacin for the treatment of community-acquired pneumonia: A pooled data analysis of two studies
51. Breakthrough sepsis in macrolide-resistant pneumococcal infection
52. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy
53. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
54. Bacteremic pneumonia due to multidrug resistant pneumococci in three patients treated unsuccessfully with azithromycin and successfully with levofloxacin
55. The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: The rip of the iceberg?